Muazzam K.

Muazzam K. has a wealth of experience in CMC and Process Development in the biotechnology industry. From 2009 to present, they have held roles at Lonza, MedImmune, Adaptimmune, Celonic Group, DiNAQOR, and Memo Therapeutics AG. Muazzam's roles have included Research Engineer, DSP Process Development Scientist, Senior Scientist - Viral Vector Process Development, DSP Manager (Process Development), and Head of CMC. At DiNAQOR DiNAMIQS, they were Head of Program Management, offering Viral Vector services to the Gene Therapy community. At DiNAQOR, they were Head of CMC, managing multiple Gene Therapy projects from early phases and transitioning them to clinical development. At Celonic Group, they were DSP Manager (Process Development), responsible for development of non-MAb customer products and platform owner for Bispecifics Abs, AAV, EVs and mRNA processes. At Adaptimmune, they were Senior Scientist - Viral Vector Process Development, leading DSP CMC activities on multiple Biologics and ATMP projects. At MedImmune, they were a DSP Process Development Scientist, developing multiple antibody therapies in phase 1/2 clinical trials. At Lonza, they were a Research Engineer, demonstrating the advantages of the simplex method for rapid process optimization over traditional DoE methods.

Muazzam K. began their education at UCL in 2004, where they earned a BEng in Biochemical Engineering. Muazzam then furthered their studies at UCL, completing a Master of Engineering - MEng in Biochemical Engineering and Process Management in 2008. Finally, Muazzam K. earned an EngD in Biochemical Engineering and Bioprocess leadership from UCL in 2013.